Pathogenesis and Treatment of Myeloma-Related Bone Disease

Int J Mol Sci. 2022 Mar 14;23(6):3112. doi: 10.3390/ijms23063112.

Abstract

Multiple myeloma is a hematologic malignancy of plasma cells that causes bone-destructive lesions and associated skeletal-related events (SREs). The pathogenesis of myeloma-related bone disease (MBD) is the imbalance of the bone-remodeling process, which results from osteoclast activation, osteoblast suppression, and the immunosuppressed bone marrow microenvironment. Many important signaling cascades, including the RANKL/RANK/OPG axis, Notch signaling, the Wnt/β-Catenin signaling pathways, and signaling molecules, such as DKK-1, sclerostin, osteopontin, activin A, chemokines, and interleukins are involved and play critical roles in MBD. Currently, bisphosphonate and denosumab are the gold standard for MBD prevention and treatment. As the molecular mechanisms of MBD become increasingly well understood, novel agents are being thoroughly explored in both preclinical and clinical settings. Herein, we will provide an updated overview of the pathogenesis of MBD, summarize the clinical management and guidelines, and discuss novel bone-modifying therapies for further management of MBD.

Keywords: bisphosphonates; denosumab; myeloma; myeloma bone disease; novel agents; osteoclastogenesis.

Publication types

  • Review

MeSH terms

  • Bone Diseases* / etiology
  • Bone Diseases* / pathology
  • Bone Diseases* / therapy
  • Diphosphonates / therapeutic use
  • Humans
  • Multiple Myeloma* / complications
  • Multiple Myeloma* / drug therapy
  • Osteoclasts / metabolism
  • RANK Ligand / metabolism
  • Tumor Microenvironment
  • Wnt Signaling Pathway

Substances

  • Diphosphonates
  • RANK Ligand